Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Quest Diagnostics (DGX) and OrganiGram Holdings (OGI)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Harmony Biosciences Holdings (HRMY – Research Report), Quest Diagnostics (DGX – Research Report) and OrganiGram Holdings (OGI – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings received a Hold rating and a $46.00 price target from UBS analyst Ashwani Verma today. The company’s shares closed last Tuesday at $37.93.
According to TipRanks.com, Verma is a 4-star analyst with an average return of
Currently, the analyst consensus on Harmony Biosciences Holdings is a Strong Buy with an average price target of $47.25.
See today’s best-performing stocks on TipRanks >>
Quest Diagnostics (DGX)
UBS analyst Kevin Caliendo maintained a Hold rating on Quest Diagnostics today and set a price target of $210.00. The company’s shares closed last Tuesday at $205.35.
According to TipRanks.com, Caliendo is a 4-star analyst with an average return of
Currently, the analyst consensus on Quest Diagnostics is a Moderate Buy with an average price target of $216.67, which is an 11.3% upside from current levels. In a report released today, Citi also maintained a Hold rating on the stock with a $215.00 price target.
OrganiGram Holdings (OGI)
Canaccord Genuity analyst Kenric Tyghe reiterated a Buy rating on OrganiGram Holdings today and set a price target of C$3.00. The company’s shares closed last Tuesday at $1.39.
According to TipRanks.com, Tyghe is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for OrganiGram Holdings with a $2.49 average price target, a 56.6% upside from current levels. In a report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a C$4.00 price target.
